Universal Access and Affordable Medicines | Analysis & Opinion

Cancer patients can’t wait any longer for action on access to affordable medicines

by European Public Health Alliance | Jun 30, 2022 | Universal Access and Affordable Medicines | Analysis & Opinion

By Dr Ward Rommel, Chair, Access to Medicines Task Force, Association of European Cancer Leagues (ECL) The research and innovation pathway for cancer medicines is challenging from basic research to market access. These challenges comprise high unmet needs, disparities...

After the storm: Lessons, teachings and possibilities of the TRIPS waivers proposal

by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion

Guest article Jaume Vidal, Senior Policy Advisor at Health Action International (HAI) In October 2020 in the midst of the COVID-19 pandemic, South Africa and India submitted a proposal to waiver certain dispositions of the Trade- Related aspects of Intellectual...

Fairer access to medicines: what needs to change in the revised EU pharma legislation

by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion

Guest article by Ancel·la Santos, Senior Health Policy Officer, The European Consumer Organisation (BEUC) To ensure recovery when facing health issues and a better quality of life among European citizens, it is essential that people get timely access to medicines and...

Why patients cannot access to medicines they need in Europe

by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion

Guest article by Charlotte Roffiaen, European Policy Advisor at France Assos Santé For many years, the increasing prices of innovative medicines have focused the attention of the European public health community. Affordability issues were threatening both patient...

Restoring the balance in EU health policies: lessons learned from the Structured Dialogue on the security of medicines supply

by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion

Article by Julia Aube, Policy Trainee for Healthcare Delivery The COVID-19 pandemic has jeopardised the access and availability of medicines in the EU, therefore, making the EU more resilient regarding the supply of pharmaceuticals is a key objective of...

European Parliament’s special committee on COVID-19 is an opportunity to drive health equity forward

The European Parliament is undertaking an extremely important task of examining how the European Union has dealt with the response to the ongoing COVID-19 pandemic. We know that its impact on almost every aspect of our lives and livelihoods has been and often...